Shionogi inks govt deal for COVID-19 therapy supply

25 March 2022
shionogi-big

Japanese pharma major Shionogi (TYO: 4507) saw its shares gain 4.5% to 7,904 yen today announced a basic agreement with the Ministry of Health, Labor and Welfare (MHLW) for the supply of S-217622, an orally administered antiviral drug for COVID-19, in Japan.

The basic agreement was concluded on the condition that Shionogi initiates manufacturing and marketing of S-217622 after receiving regulatory approval in Japan. This is the first such contract for a domestically-produced oral therapeutic drug for COVID-19. The main provision is that the company and the MHLW will advance negotiations toward the conclusion of a purchasing contract and a distribution consignment contract until regulatory approval is obtained.

The expectation is that the Japanese government will purchase 1 million courses of S-217622 immediately after approval, so that S-217622 can be widely provided to COVID-19 patients, primarily in Japan, and will continue to purchase a certain number of courses of S-217622 after that.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical